CY1122419T1 - Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl - Google Patents

Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl

Info

Publication number
CY1122419T1
CY1122419T1 CY20191101302T CY191101302T CY1122419T1 CY 1122419 T1 CY1122419 T1 CY 1122419T1 CY 20191101302 T CY20191101302 T CY 20191101302T CY 191101302 T CY191101302 T CY 191101302T CY 1122419 T1 CY1122419 T1 CY 1122419T1
Authority
CY
Cyprus
Prior art keywords
heavy chain
human
light chain
human immunoglobulin
dehumanized
Prior art date
Application number
CY20191101302T
Other languages
Greek (el)
English (en)
Inventor
Lynn Macdonald
Cagan Gurer
Karolina A. MEAGHER
Sean Stevens
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1122419T1 publication Critical patent/CY1122419T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Central Heating Systems (AREA)
  • Housing For Livestock And Birds (AREA)
CY20191101302T 2012-02-01 2019-12-10 Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl CY1122419T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
CY1122419T1 true CY1122419T1 (el) 2021-01-27

Family

ID=47714588

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101302T CY1122419T1 (el) 2012-02-01 2019-12-10 Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl
CY20211100659T CY1124361T1 (el) 2012-02-01 2021-07-20 Εξανθρωπισμενα τρωκτικα που εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100659T CY1124361T1 (el) 2012-02-01 2021-07-20 Εξανθρωπισμενα τρωκτικα που εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl

Country Status (26)

Country Link
US (3) US20130212719A1 (OSRAM)
EP (3) EP3597038B1 (OSRAM)
JP (6) JP2015505477A (OSRAM)
KR (2) KR20190006029A (OSRAM)
CN (2) CN104202971B (OSRAM)
AU (3) AU2013204758B2 (OSRAM)
BR (1) BR112014018843B1 (OSRAM)
CA (1) CA2863175A1 (OSRAM)
CY (2) CY1122419T1 (OSRAM)
DK (2) DK2809150T3 (OSRAM)
ES (2) ES2753774T3 (OSRAM)
HR (2) HRP20192218T1 (OSRAM)
HU (2) HUE046744T2 (OSRAM)
IL (3) IL233827A0 (OSRAM)
LT (2) LT3597038T (OSRAM)
ME (1) ME03611B (OSRAM)
MX (2) MX373286B (OSRAM)
NZ (5) NZ734504A (OSRAM)
PL (2) PL2809150T3 (OSRAM)
PT (2) PT3597038T (OSRAM)
RS (2) RS62023B1 (OSRAM)
RU (2) RU2770016C2 (OSRAM)
SG (3) SG11201404477YA (OSRAM)
SI (2) SI3597038T1 (OSRAM)
SM (2) SMT202100401T1 (OSRAM)
WO (1) WO2013116609A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
CA3250882A1 (en) * 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
HUE055617T2 (hu) 2012-06-12 2021-12-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
ES2678221T3 (es) 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
CA2979702A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3277823B1 (en) * 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CA3017678A1 (en) * 2016-04-04 2017-10-12 Eth Zurich Mammalian cell line for protein production and library generation
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
WO2018183946A1 (en) * 2017-03-30 2018-10-04 Utah State University Transgenic silkworms expressing spider silk
CN116058333A (zh) * 2017-12-05 2023-05-05 瑞泽恩制药公司 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途
LT3772927T (lt) * 2018-03-24 2025-02-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės arba žiurkės, skirtos gaminti terapinius antikūnus prieš peptidų- mhc kompleksus, jų gamybos būdai ir panaudojimas
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
EA007958B1 (ru) * 2000-08-03 2007-02-27 Терапеутик Хьюман Поликлоналз Инк. ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
AU2002357410A1 (en) 2001-12-21 2003-07-09 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
WO2003081993A2 (en) * 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
ES2473596T3 (es) * 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
CA2584814A1 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in non-human transgenic animals
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101506235B (zh) * 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
BRPI0815848A2 (pt) * 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
CL2008002886A1 (es) * 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
EP2556747B1 (en) * 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
EP2331689A4 (en) * 2008-08-29 2012-10-31 Symphogen As METHOD OF CLONING AVIAN ORIGIN ANTIBODIES
US9085795B2 (en) * 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
PT2564695E (pt) * 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
CA3250882A1 (en) * 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
SI2738258T2 (sl) * 2011-02-25 2023-05-31 Regeneron Pharmaceuticals, Inc. Miši ADAM6
MY172718A (en) * 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
KR102081657B1 (ko) * 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
HUE055617T2 (hu) * 2012-06-12 2021-12-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
DK3766343T3 (da) * 2016-11-04 2022-06-20 Regeneron Pharma Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus

Also Published As

Publication number Publication date
BR112014018843A8 (pt) 2019-01-29
BR112014018843B1 (pt) 2024-02-20
JP7187615B2 (ja) 2022-12-12
ME03611B (me) 2020-07-20
CN106117364B (zh) 2021-08-31
IL261280B (en) 2019-08-29
SI2809150T1 (sl) 2019-11-29
HUE046744T2 (hu) 2020-03-30
PT2809150T (pt) 2019-12-09
IL268675B (en) 2020-11-30
ES2870703T3 (es) 2021-10-27
KR20140123983A (ko) 2014-10-23
SG10201606256TA (en) 2016-09-29
SI3597038T1 (sl) 2021-07-30
KR20190006029A (ko) 2019-01-16
MX2019002517A (es) 2019-06-17
SMT201900685T1 (it) 2020-01-14
JP6942757B2 (ja) 2021-09-29
JP2023014242A (ja) 2023-01-26
HUE055610T2 (hu) 2021-12-28
AU2013204758B2 (en) 2015-07-23
BR112014018843A2 (pt) 2017-07-04
JP7525579B2 (ja) 2024-07-30
SG10201913428QA (en) 2020-03-30
NZ627977A (en) 2016-06-24
JP2023168590A (ja) 2023-11-24
JP6698718B2 (ja) 2020-05-27
PL3597038T3 (pl) 2021-11-08
US20170094955A1 (en) 2017-04-06
JP2015505477A (ja) 2015-02-23
ES2753774T3 (es) 2020-04-14
EP2809150A1 (en) 2014-12-10
HRP20192218T1 (hr) 2020-03-06
RS59699B1 (sr) 2020-01-31
AU2013204758A1 (en) 2013-08-15
JP2021137030A (ja) 2021-09-16
RU2770016C2 (ru) 2022-04-14
AU2017251848A1 (en) 2017-11-16
PT3597038T (pt) 2021-05-10
RS62023B1 (sr) 2021-07-30
CN106117364A (zh) 2016-11-16
RU2664185C2 (ru) 2018-08-15
US20130212719A1 (en) 2013-08-15
CA2863175A1 (en) 2013-08-08
HK1202771A1 (en) 2015-10-09
DK3597038T3 (da) 2021-06-28
CY1124361T1 (el) 2022-07-22
PL2809150T3 (pl) 2020-04-30
MX2020003491A (es) 2022-10-25
US20210368751A1 (en) 2021-12-02
CN104202971A (zh) 2014-12-10
CN104202971B (zh) 2016-07-06
IL268675A (en) 2019-10-31
AU2015246154A1 (en) 2015-11-12
LT3597038T (lt) 2021-05-25
SG11201404477YA (en) 2014-08-28
JP2019170395A (ja) 2019-10-10
EP3597038A1 (en) 2020-01-22
NZ734504A (en) 2022-10-28
AU2017251848B2 (en) 2020-02-20
RU2018122695A3 (OSRAM) 2021-10-06
SMT202100401T1 (it) 2021-09-14
WO2013116609A1 (en) 2013-08-08
EP3597038B1 (en) 2021-04-21
DK2809150T3 (da) 2019-12-09
HRP20210987T1 (hr) 2021-09-17
IL233827A0 (en) 2014-09-30
IL261280A (en) 2018-10-31
JP2018075041A (ja) 2018-05-17
EP2809150B1 (en) 2019-09-18
NZ793447A (en) 2024-05-31
EP3912465A1 (en) 2021-11-24
AU2015246154B2 (en) 2017-11-23
NZ810648A (en) 2025-11-28
LT2809150T (lt) 2019-10-25
MX373286B (es) 2020-05-20
RU2014133653A (ru) 2016-03-20
NZ719228A (en) 2022-08-26
RU2018122695A (ru) 2019-03-06

Similar Documents

Publication Publication Date Title
CY1122419T1 (el) Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl
CY1121638T1 (el) Ποντικοι με εξανθρωπισμενη ελαφρια αλυσιδα
CY1124320T1 (el) Ανθρωποποιημενα μη ανθρωπινα ζωα με περιορισμενους τοπους βαριας αλυσιδας ανοσοσφαιρινης
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1121608T1 (el) Ποντικια που δημιουργουν αντισωματα βαριας αλυσιδας
CY1122940T1 (el) Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο προγραμματισμενου κυτταρικου θανατου 1
CY1122205T1 (el) Ποντικοι adam6
CY1122409T1 (el) Σχεδιασμος σταθερου ετεροδιμερικου αντισωματος με μεταλαξεις στην επικρατεια fc
CY1119071T1 (el) Εξανθρωποποιημενα il-7 τρωκτικα
CY1121864T1 (el) Τρωκτικα που εκφραζουν ευαισθητες στο ρη αλληλουχιες ανοσοσφαιρινης
CY1123215T1 (el) Πολυνουκλεοτιδια τα οποια κωδικοποιουν αντισωματα τρωκτικων με ανθρωπινους ιδιοτυπους και ζωα τα οποια διαθετουν αυτα
CY1121979T1 (el) Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις
IL280004A (en) Antibody molecules that bind pd-l1 and cd137
CY1124108T1 (el) Μορια συνδεσης που αναστελουν την αναπτυξη καρκινου
CY1120626T1 (el) Αντισωματα και αλλα μορια που δεσμευουν β7-η1 και pd-1
CY1124358T1 (el) Ευκολως απομονωμενα διειδικα αντισωματα με φυσικης ανοσοσφαιρινης μορφη
CY1124605T1 (el) Ζωα με εξανθρωπισμενα il-4 και il-4r αλφα
CY1121545T1 (el) Ποντικοι που εκφραζουν περιορισμενο ρεπερτοριο ελαφριων αλυσιδων ανοσοσφαιρινης
CY1118923T1 (el) ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ
CY1119691T1 (el) Παραγοντες συνδεσης cd33
EP2995682A4 (en) NUCLEIC ACID OF CODED CHIMERIC GPC3 ANTIGEN RECEPTOR PROTEIN AND T-LYMPHOCYTES EXPRESSIVE CHIMERIC GPC3 ANTIGEN RECEPTOR PROTEIN
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
EP3538135A4 (en) POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
MX363022B (es) Roedores humanizados que expresan cadenas pesadas que contienen dominios vl.
Martin Re-thinking our professional identity in light of new responsibilities